硕世生物 (688399.SH) Stock Price, Financials & Summary | drillr

Skip to content

Sign in Sign up

Price chart

Aug 6Aug 11Aug 14Aug 19Aug 24Aug 27Sep 1Sep 4

ValuationView details →

P/E (Fwd)

—

EV/EBITDA

69.3x

Market Cap

CNY 3.46B

MomentumView details →

1D Return

−2.76%

YTD Return

—

RSI (14)

36.3

ValuationView details →

P/E (Fwd)

—

EV/EBITDA

69.3x

Market Cap

CNY 3.46B

RSI (14)

36.3

MomentumView details →

1D Return

−2.76%

YTD Return

—

ProfitabilityView details →

Gross Margin

63.55%

Net Margin

−10.05%

EBITDA Margin

14.98%

ROE (TTM)

−1.11%

ROA (TTM)

−0.89%

Asset Turnover

0.09x

GrowthView details →

Revenue YoY

−6.88%

EPS YoY

−36.99%

FCF YoY

—

Revenue CAGR 3Y

−60.58%

EPS CAGR 3Y

—

EBITDA YoY

—

EarningsView details →

EPS (Actual)

—

EPS Surprise

—

Beats (12Q)

—

Next Q EPS Est

—

Avg Surprise (4Q)

—

Rev Surprise

—

Capital & dividendView details →

Debt/Equity

0.18x

Current Ratio

3.33x

Quick Ratio

3.25x

Div Yield

18.69%

Div Rate

CNY 5.03

Div Growth 1Y

−49.68%

Financials snapshotView financials →

Revenue (TTM)

326.02M

Net Income (TTM)

−32.78M

Op. CF (TTM)

23.43M

Latest newsMore news →

Suzhou Sursen Biopharmaceutical Co., Ltd. announced its 2026 first-half results: net profit attributable to shareholders was 19.5646 million yuan, up 390.02% year-on-year, with revenue of 147 million yuan, down 16.03%.8d ago

Similar companies

Veracyte, Inc.VCYT 普莱柯603566.SH Structure Therapeutics Inc.GPCR Denali Therapeutics Inc.DNLI HJ Science Co., Ltd.06132.HK 申联生物688098.SH Find similar companies →

Latest newsMore news →

Suzhou Sursen Biopharmaceutical Co., Ltd. announced its 2026 first-half results: net profit attributable to shareholders was 19.5646 million yuan, up 390.02% year-on-year, with revenue of 147 million yuan, down 16.03%.8d ago